These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 12488554)
1. Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Yin D; He Y; Perera MA; Hong SS; Marhefka C; Stourman N; Kirkovsky L; Miller DD; Dalton JT Mol Pharmacol; 2003 Jan; 63(1):211-23. PubMed ID: 12488554 [TBL] [Abstract][Full Text] [Related]
2. Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain. Söderholm AA; Lehtovuori PT; Nyrönen TH J Med Chem; 2005 Feb; 48(4):917-25. PubMed ID: 15715462 [TBL] [Abstract][Full Text] [Related]
3. Chiral nonsteroidal affinity ligands for the androgen receptor. 1. Bicalutamide analogues bearing electrophilic groups in the B aromatic ring. Kirkovsky L; Mukherjee A; Yin D; Dalton JT; Miller DD J Med Chem; 2000 Feb; 43(4):581-90. PubMed ID: 10691684 [TBL] [Abstract][Full Text] [Related]
4. Affinity labeling of the androgen receptor with nonsteroidal chemoaffinity ligands. Mukherjee A; Kirkovsky LI; Kimura Y; Marvel MM; Miller DD; Dalton JT Biochem Pharmacol; 1999 Oct; 58(8):1259-67. PubMed ID: 10487527 [TBL] [Abstract][Full Text] [Related]
5. Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. He Y; Yin D; Perera M; Kirkovsky L; Stourman N; Li W; Dalton JT; Miller DD Eur J Med Chem; 2002 Aug; 37(8):619-34. PubMed ID: 12161060 [TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring. Chen J; Hwang DJ; Chung K; Bohl CE; Fisher SJ; Miller DD; Dalton JT Endocrinology; 2005 Dec; 146(12):5444-54. PubMed ID: 16166218 [TBL] [Abstract][Full Text] [Related]
7. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay. Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690 [TBL] [Abstract][Full Text] [Related]
8. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440 [TBL] [Abstract][Full Text] [Related]
9. Discovery of nonsteroidal androgens. Dalton JT; Mukherjee A; Zhu Z; Kirkovsky L; Miller DD Biochem Biophys Res Commun; 1998 Mar; 244(1):1-4. PubMed ID: 9514878 [TBL] [Abstract][Full Text] [Related]
10. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. Bohl CE; Miller DD; Chen J; Bell CE; Dalton JT J Biol Chem; 2005 Nov; 280(45):37747-54. PubMed ID: 16129672 [TBL] [Abstract][Full Text] [Related]
11. Structural Dynamics of Agonist and Antagonist Binding to the Androgen Receptor. Azhagiya Singam ER; Tachachartvanich P; La Merrill MA; Smith MT; Durkin KA J Phys Chem B; 2019 Sep; 123(36):7657-7666. PubMed ID: 31431014 [TBL] [Abstract][Full Text] [Related]
12. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations. Liu H; An X; Li S; Wang Y; Li J; Liu H Mol Biosyst; 2015 Dec; 11(12):3347-54. PubMed ID: 26442831 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of [18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br]bromo-thiobicalutamide as non-steroidal androgens for prostate cancer imaging. Parent EE; Dence CS; Jenks C; Sharp TL; Welch MJ; Katzenellenbogen JA J Med Chem; 2007 Mar; 50(5):1028-40. PubMed ID: 17328524 [TBL] [Abstract][Full Text] [Related]
15. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile as a high-affinity nonsteroidal androgen receptor ligand. Van Dort ME; Robins DM; Wayburn B J Med Chem; 2000 Aug; 43(17):3344-7. PubMed ID: 10966753 [TBL] [Abstract][Full Text] [Related]
18. Nonsteroidal selective androgen receptor modulators enhance female sexual motivation. Jones A; Hwang DJ; Duke CB; He Y; Siddam A; Miller DD; Dalton JT J Pharmacol Exp Ther; 2010 Aug; 334(2):439-48. PubMed ID: 20444881 [TBL] [Abstract][Full Text] [Related]
19. A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. Bohl CE; Chang C; Mohler ML; Chen J; Miller DD; Swaan PW; Dalton JT J Med Chem; 2004 Jul; 47(15):3765-76. PubMed ID: 15239655 [TBL] [Abstract][Full Text] [Related]
20. The amino terminus of the human AR is target for corepressor action and antihormone agonism. Dotzlaw H; Moehren U; Mink S; Cato AC; Iñiguez Lluhí JA; Baniahmad A Mol Endocrinol; 2002 Apr; 16(4):661-73. PubMed ID: 11923464 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]